Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma

Table 2 Serum prolidase and α-fetoprotein levels of different tumor related factors in patients with hepatocellular carcinoma

Variables	n = 68	AFP (ng/L) median (min-max)	P value	Prolidase (U/L) median (min-max)	P value
Tumor size (cm)
≤ 3	19	440 (2.5-2000)	0.032	1120 (1080-1250)	< 0.001
3-5	12	548 (45-1740)		1178 (1123-1260)
≥ 5	37	850 (73-2300)		1219 (1113-1600)
Tumor number
1	29	547 (2.5-2248)	0.038	1150 (1080-1310)	0.002
2	13	550 (9-1430)		1142 (1110-1265)
≥ 3	26	1160 (84-2300)		1222 (1120-1600)
Macrovascular invasion
No	59	597 (2.5-2300)	0.502	1174 (1080-1600)	0.575
Yes	9	770 (110-1750)		1208 (1120-1276)
BCLC staging
A	20	470 (2.5-2000)	0.015	1128 (1080-1260)	< 0.001
B	29	862 (78-2300)		1219 (1123-1600)
C	8	867 (110-1645)		1174 (1120-1276)
D	11	615 (73-2050)		1150 (1113-1286)

AFP: Alpha fetoprotein; BCLC: The Barcelona-Clinic Liver Cancer Group; HCC: Hepatocellular carcinoma.